Respiratory News and Research

RSS

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

Cornerstone Therapeutics Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Rotech Healthcare second-quarter adjusted EBITDA increases to $29.2 million

Rotech Healthcare Inc. today announced financial results for the three and six months ended June 30, 2010.

5 Aug 2010

Hayfever: time we moved exams to the winter?

Crucial exams take place during adolescence in most societies, which can have a major impact on an individual’s career trajectory. In a Guest Editorial appearing in the August issue of Expert Review of Respiratory Medicine, a team of UK experts review the evidence of the disease burden associated with hayfever and summarize recent evidence suggesting that poorly controlled hayfever can adversely impact on exam performance.

5 Aug 2010

Mothers of premature babies have high levels of stress and anxiety

The incidence of premature babies has been stable or even increased over time. The phenomenon brings with it the possibility of neurological, sensorial, respiratory, cognitive or psychomotor consequences for the child, both in the short and the medium term. These consequences also are a concern to child psychiatrists and psychologists, as it is currently known that the progress of a premature baby and the appearance or otherwise of problems depend largely on the family environment, above all how the mother interacts with her child in the first months of its life.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Optimer second-quarter net loss decreases to $10.4 million

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.

5 Aug 2010

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and reports financial results for the second quarter ended June 30, 2010.

4 Aug 2010

WHO provides medicines, related health supplies to flood-affected areas in Pakistan

The worst floods on record in Pakistan are placing the health of hundreds of thousands of people at risk, with a high threat of waterborne disease outbreaks and immense damage to health facilities. WHO is coordinating the response of health partners and supporting Pakistani authorities by sending medicines and related health supplies capable of treating more than 200 000 people to the affected areas in the northwestern region of the country.

4 Aug 2010

Study analyzes prevalence of pediatric patient-safety events at hospitals

Hospital-acquired infections are the leading cause of potentially preventable mortality among pediatric patients, according to a study of pediatric patient-safety incidents issued today by HealthGrades, the leading independent health care ratings organization.

4 Aug 2010

Cornerstone licenses global rights to alpha-7 technology to Targacept

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.

4 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Water Street Healthcare Partners acquires Medical Specialties Distributors

Water Street Healthcare Partners, a leading private equity firm focused exclusively on health care, announced today that it has acquired Medical Specialties Distributors, LLC (MSD). Headquartered in Stoughton, Massachusetts, MSD is the nation's leading provider of infusion products, supplies, biomedical services and technology solutions to the growing home infusion therapy market. The acquisition expands Water Street's current group of health care companies to 12.

From Baxter International Inc. 31 Jul 2010

The House fails to pass aid measure for sick 9/11 responders

The Associated Press: "A bill that would have provided up to $7.4 billion in aid to people sickened by World Trade Center dust fell short in the House on Thursday, raising the possibility that the bulk of compensation for the ill will come from a legal settlement hammered out in the federal courts." The measure failed to draw the necessary two-thirds majority. Democrats had opted for this procedural route rather than a simple majority because it blocked potential GOP amendments.

31 Jul 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

Respiratory symptoms are accurate indicators of influenza infection

New research shows that individuals with mild H1N1 infection may go undetected using standard diagnostic criteria, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, (APIC). The study concludes that coughing or other respiratory symptoms are more accurate in determining influenza infection than presence of a fever.

30 Jul 2010

Orexigen's Contrave COR-I trial results published online in journal Lancet

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

30 Jul 2010

New paradigm in TB research may lead to improved vaccination, treatment

Often causing no symptoms in carriers of the disease, worldwide tuberculosis (TB) infects eight to ten million people every year, kills two million, and it is highly contagious as it is spread through coughing and sneezing. "It's a global health disaster waiting to happen, even here in Canada, but this new paradigm in TB research may offer an immediate opportunity to improve vaccination and treatment initiatives," explains Dr. Maziar Divangahi of McGill University and of the Research Institute of the McGill University Health Centre.

30 Jul 2010

Quidel second-quarter total revenues increase 1.6% to $25.0 million

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today financial results for the second quarter ended June 30, 2010.

30 Jul 2010

Gentiva Health Services second-quarter total net revenues increase 4% to $297.1 million

Gentiva Health Services, Inc., a leading provider of home health and hospice services, today reported second quarter 2010 results.

29 Jul 2010

Senate Commission presents 2010 list of MAK and BAT values containing new data on 61 substances

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.

29 Jul 2010